Purchased 97.5 contiguous acres (39.5 hectares) adjacent to the original Langton facility to support further expansion of growth operations in Canada.
Earned Health Canada license to sell cannabis extracts, expanding the company’s ability to develop and sell products in new and innovative formats.
First sale of bottled cannabis oil, leveraging the Health Canada license to sell cannabis extracts obtained in September 2016.
Broke ground on Phase I of the Langton expansion, which would add 217,000 square feet (20,159 square meters) of greenhouse space to the facility.
Founded Maricann GMBH, a new subsidiary in located in Munich, Germany, putting Maricann in a position to take advantage of opportunities in the recently legalized medical cannabis industry in Germany.
Commenced sale of clones in Canada.
Completed Reservation Agreement for Ebersbach facility, near Dresden, Germany, which would provide additional processing capabilities for Mariplant GmbH.
Started retrofit of Ebersbach facility for which the Company held an option to purchase, which would allow the facility to accommodate drying equipment able to process 1,000kg of wet cannabis per hour.
Completed RTO transaction and initial listing on the Canadian Securities Exchange (CSE), changing the company from the privately-held Maricann Inc. to the publicly traded Maricann Group Inc.
Established a new subsidiary in Germany called Maricann GmbH, putting Maricann in a position to take advantage of opportunities in the recently legalized medical cannabis industry in Germany.
Completed 75,000 square feet (6,967 square meters) expansion of Ebersbach facility for which the Company held an option to purchase, as part of a 400,000 square foot expansion plan.
Acquired 100% of the issued and outstanding shares of NanoLeaf Technologies Inc., strengthening Maricann’s innovation pipeline through the rights to globally patented technologies .
Secured a second-site sales license for its office location in Burlington, Ontario, allowing greater efficiencies in sales, marketing, and customer service, as well as analytical testing and bench services onsite.
Completed the process of acquiring NanoLeaf Technologies Inc. initiated in August 2017.
Partnered with International Cannabrands Ltd. and Julian Marley, giving Maricann the exclusive right to cultivate, extract, and distribute JuJu Royal ™ products in Canada and first right of refusal in western Europe
Scott Langille appointed as the Company’s Chief Financial Officer, bringing over 30 years of pharmaceutical experience in Canada and the US.
Began work with Rockwell Automation to develop a connected, scalable plant-wide platform to connect the key functions of Maricann’s cultivation facility to produce a consistent, high-yield crop.
Signed a Definitive Agreement with Lovell Drugs as part of the Medical Cannabis Retail Pharmacy Initiative. This allows Maricann to be the exclusive provider of medical cannabis to Lovell pharmacies, in addition to supporting continuing education for Lovell Drugs personnel and patients.
Entered into an exclusivity agreement to bring Rare Dankness genetics to Canada as the exclusive distribution partner. The contract also includes first right of refusal to act as their exclusive distributor in Europe.
Raised $40MM by way of private placement, to be used for facility expansion, working capital, and general corporate purposes, including continuing to expand the production facility in Langton.
Initiated a letter of intent to acquire Haxxon AG, which operates a 60,000 sq. ft. facility cultivating female hemp cannabis flowers in Regensdorf, Switzerland. This acquisition would allow Maricann to manufacture finished low-THC products outside of their current offerings.
Completed Phase I of the expansion of the state-of-the-art facility in Langton, Ontario, which increased the company’s annual growing capacity to 25,000kg of dried flower per year.
Planted the first seeds at MariPlant’s hemp cultivation site in Saxony, Germany, focused on producing isolates of CBD and CBG for Mariplant products sold across Germany and the greater EU.
Signed a definitive agreement to acquire all of the outstanding shares of Haxxon AG (initiated in January 2018) as part of the company’s European expansion strategy.
Received first export permit from Health Canada that would allow the shipment of packaged dry cannabis flowers to Germany, as part of the company’s European expansion strategy.
Received third site license to allow cultivation in the Phase 1 expansion of the Langton facility.
Joined an exclusive group of Canadian Licensed Producers to be Good Manufacturing Practice (GMP) certified in accordance with the European Medicines Agency’s GMP standards. This certification is regarded as the highest assurance of quality and safety that a pharmaceutical manufacturer can receive.
MariPlant GmbH commenced the harvest of approximately 165 hectares (~405 acres) of hemp. MariPlant GmbH planted five approved cultivars included in the European Union list of approved hemp.
Closed a private placement offering (the “August SW Offering”) of special warrants (the “August Special Warrants”) for aggregate gross proceeds of $37,401,760.
Following passage of Bill C-45 legalizing the sale and use of recreational cannabis across Canada, Maricann Group announced supply agreements with Manitoba, Alberta and a Memorandum of Understanding with British Columbia for an annualized total of 10,923 kg of cannabis.
Maricann ships first batch of dried flower from Canada to Germany, which met all specifications and requirements upon import.
Maricann announces shipment of CBD capsules in Germany with VESIsorb technology.
First recreational brand launch in Canada. Kiwi, a brand including products with low to mid-THC strains, is announced for sale in some Canadian provinces as of October 17, 2018.
Maricann Group announces intent to change name to Wayland Group, including changing its ticker symbol on the Canadian Securities Exchange from MARI to WAYL.
Wayland announces plans for first retail location in Zurich, Switzerland, which will retail cannabis products containing a maximum THC content of 1 percent.
Wayland received accreditation for its proprietary medical cannabis profession educational program for pharmacists, which will be available in 2100 pharmacies across Canada.
Wayland successfully exports THC distillate from Canada to Switzerland that met the standards suitable for product commercialization in Switzerland, marking the second country to which Wayland has successfully exported cannabis products.
Wayland raises $50,077,500 by way of a Bought Deal with a syndicate of underwriters led by Cannacord Genuity Corp.
Wayland signs the first significant European supply agreement of a minimum of 9000kg of EU-GMP certified cannabis flower over 3 years with Cannamedical Pharma GmbH.
Wayland receives Sales License for new, state-of-the-art cannabis production facility in Norfolk, Ontario.
Launched full Canadian non-medical brand lineup, with some brands available for sale in select Canadian provinces as of October 17, 2018. Wayland’s full lineup of Canadian non-medical brands includes Kiwi, High Tide, Northern Harvest, Lost at Seed, Solara C, and Rare Dankness.
Hemp harvest of 135 acres in Germany exceeds internal forecasts by a factor of two, as a result of proprietary and customized harvesting equipment and drying systems.
Entered into an agreement to acquire 100% of the outstanding shares of Colma Pharmaceutical SAS, a licensed producer of THC cannabis in Ibague, Colombia, marking Wayland’s first venture in South America.
Clay Horner and Rudi Hilti appointed to Board of Directors, bringing expertise in corporate governance, global strategy, finance, and M&A expertise.
Completed a definitive joint venture agreement with CBD Italian Factory S.S., a producer of cannabis products in Italy, allowing for the sustainable production of CBD and THC products in Italy.